NEW YORK, April 22, 2016 (GLOBE NEWSWIRE) -- Safirstein Metcalf LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of all those who purchased Horizon Pharma PLC (“Horizon” or the “Company”) (NASDAQ: HZNP ) securities between March 13, 2014 and February 26, 2016 (the "Class Period").
If you purchased Horizon securities during the Class Period, you may, no later than May 9 2016 , request that the Court appoint you lead plaintiff of the proposed class. A lead plaintiff is a representative party that acts on behalf of all class members in directing the litigation. Any member of the purported class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
If you want more information about the Horizon securities class action, contact Sheila Feerick at Safirstein Metcalf LLP, 1-800-221-0015 or email info@SafirsteinMetcalf.com or at www.safirsteinmetcalf.com/horizon-pharma.html
The lawsuit alleges that the company made materially false and/or misleading statements and/or failed to disclose that its Prescriptions-Made-Easy (“PME”) program was designed to artificially inflate the prices of minor differentiation standard retail drugs. Additionally, the company allegedly failed to inform investors that sales revenues from drugs sold through Horizon’s PME program were unsustainable and that HZNP’s PME program left the company subject to increased regulatory risks.
The complaint also states that Horizon failed to disclose that it received a subpoena from the Office of the U.S. Attorney for the Southern District of New York in November 2015; and as a result of the foregoing, statements about Horizons’ business, operations and prospects were false and misleading and/or lacked a reasonable basis.
On February 29, 2016, Horizon disclosed in its 2015 annual report that the Company received a subpoena in November 2015 from the Office of the U.S. Attorney for the Southern District of New York for documents and information related to the Company’s patient assistance programs. Following this news, Horizon’s stock fell $2.63, or 13.3%, to close at $17.16 on February 29, 2016.
About Safirstein Metcalf LLP Safirstein Metcalf LLP focuses its practice on shareholder rights. The law firm also practices in the areas of antitrust and consumer protection. All of the Firm’s legal endeavors are rooted in its core mission: provide investor and consumer protection.
Attorney advertising. Prior results do not guarantee a similar outcome.
Safirstein Metcalf LLP Peter Safirstein, Esq. 1250 Broadway 27th Floor New York, NY 10001 1-800-221-0015 info@SafirsteinMetcalf.com